Mixed trend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend down since Sep 18 · above the Ichimoku cloud · RSI 46 · MACD below its signal
| 73.00 | 52-week high | +2675.67% |
| 12.31 | Previous month high | +368.06% |
| 3.80 | Previous week high | +44.49% |
| 3.03 | R3 (classic) | +15.08% |
| 2.94 | R2 (classic) | +11.91% |
| 2.86 | Previous day high | +8.75% |
| 2.79 | R1 (classic) | +5.96% |
| 2.70 | Pivot | +2.79% |
| 2.63 | Price now | |
| 2.62 | Previous day low | −0.38% |
| 2.62 | Previous week low | −0.38% |
| 2.55 | S1 (classic) | −3.17% |
| 2.46 | S2 (classic) | −6.33% |
| 2.31 | S3 (classic) | −12.29% |
| 0.8500 | Previous month low | −67.68% |
| 0.8230 | 52-week low | −68.71% |
None of the 29 investors followed here reported a position in MEDS in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MEDS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 21, 2026 | Patel PrashantChief Executive Officer | Conversion of Exercise of derivative security at price 0.00 per share. | 100K | $500 |
| Jun 21, 2026 | Ajjarapu Surendra KDirector | Conversion of Exercise of derivative security at price 0.00 per share. | 100K | $500 |
| Mar 30, 2026 | Patel PrashantChief Executive Officer | Stock Award(Grant) at price 0.10 per share. | 5.00M | $482.00K |
| Mar 30, 2026 | Patel PrashantChief Executive Officer | Stock Award(Grant) at price 0.20 per share. | 5.00M | $1.00M |
| Mar 30, 2026 | Ajjarapu Surendra KDirector | Stock Award(Grant) at price 0.10 per share. | 5.00M | $482.00K |
| Mar 30, 2026 | Ajjarapu Surendra KDirector | Stock Award(Grant) at price 0.20 per share. | 5.00M | $1.00M |
| Jul 1, 2025 | Peterson Michael LDirector | Stock Award(Grant) at price 0.90 per share. | 200K | $180.00K |
| Mar 20, 2025 | Shanahan Rebecca MDirector | — | 200K | — |
| Mar 20, 2025 | Syed SajidDirector | — | 200K | — |
| Mar 20, 2025 | Patel PrashantOfficer and Director | — | 4.08M | — |
| Mar 20, 2025 | Ajjarapu Surendra KDirector | — | 4.08M | — |
| Mar 20, 2025 | Anderson Donald WilliamDirector | — | 200K | — |
| Mar 20, 2025 | Pirani ShafaatOfficer | — | 35K | — |
| Mar 20, 2025 | Norton BrianChief Executive Officer | — | 9.00M | — |
| Mar 20, 2025 | Panchal NikulOfficer | — | 90K | — |
TimeframesDown on the hourly and weekly, mixed on the daily.
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
under a falling 21 EMA, 21 under 50
No analyst coverage for this instrument.
DataMEDS AI, Inc. operates as a health IT company in the United States. The company focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units to deliver an enhanced healthcare experience for consumers. It offers tools, such as the EinsteinRx, a pharmacy dispensing AI platform; the PharmacyChain, a smart contracts platform; Patient Rx Adherence Tool; and HubRx AI. It also operates as a pharmacy distributor; and provides clinical concierge services. DataMEDS AI, Inc., through its subsidiary develops and delivers a portfolio of products to guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. In addition, the company develops and provides functional precision medicine oncology platform. The company was formerly known as Wellgistics Health, Inc. and changed its name to DataMEDS AI, Inc. in July 2026. DataMEDS AI, Inc. was incorporated in 2022 and is based in Tampa, Florida.